{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018499","form_type":"8-K/A","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.219924+00:00","generated_at":"2026-06-02T07:56:57.497601+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ProPhase Labs corrects Q1 EPS to $(0.35) from $(0.07); net loss $6.3M on revenue decline","bullets":["Corrected diluted EPS $(0.35) vs originally $(0.07); weighted average shares corrected to 18.0M from 90.4M.","Q1 net loss of $6.3M vs net income of $0.6M a year ago; revenue fell 81% to $3.6M as COVID testing ended.","Pharmaloz exploring potential sale or long-term capacity agreements; line two expected $40-$45M revenue capacity in Q3.","BE-Smart esophageal cancer test on track for H2 2024 commercialization; launched AI initiative Project ZenQ-AI.","Cash at April 30 was $4.6M; raised $2.5M via receivable securitization and collected $3.6M from partial investment sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018499","json":"https://secwatch.observer/filing/0001493152-24-018499.json","markdown":"https://secwatch.observer/filing/0001493152-24-018499.md","text":"https://secwatch.observer/filing/0001493152-24-018499.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315224018499/0001493152-24-018499-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315224018499/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:56:57.497601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"eabb392a51e83f44820ac89b8aae16130f5b11ab","claim":"ProPhase Labs, Inc. reported financial results for the three months ended March 31, 2024.","evidence_excerpt":"ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315224018499/0001493152-24-018499-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}